top of page
  • Safi Bello

EMA investigates Allergan blockbuster hopeful Esmya on reports of liver damage

Fierce Pharma ---------- As Allergan chases a U.S. approval for uterine fibroids drug Esmya, across the pond, regulators are investigating the treatment for liver damage.The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has launched a review of the product after four cases of serious liver damage turned up among patients, Bernstein’s Ronny Gal wrote in a note to clients. Three of those cases ended in liver transplantation, the EMA noted. To learn more click on the picture below to read the article.

EMA investigates Allergan blockbuster hopeful Esmya on reports of liver damage - Read More from Fierce Pharma

1 view
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon
bottom of page